<DOC>
	<DOCNO>NCT00004907</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug radiation therapy kill cancer cell . PURPOSE : Phase I/II trial study effectiveness chemotherapy radiation therapy plus bone marrow peripheral stem cell transplantation treat patient refractory relapse T-cell lymphoma , Hodgkin 's lymphoma , non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Plus Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Relapsed Refractory T-cell Lymphoma , Hodgkin 's Lymphoma , Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity intensive program chemoradiotherapy follow HLA identical relate bone marrow peripheral blood stem cell transplantation patient relapse refractory cutaneous T-cell lymphoma , Hodgkin 's lymphoma , non-Hodgkin 's lymphoma . - Determine response rate disease free survival patient treat regimen . OUTLINE : HLA identical related donor undergo harvest bone marrow peripheral blood stem cell ( PBSC ) . Patients assign one two treatment group base prior radiation abdomen mediastinum : - Group A ( prior radiation great 2,000 cGy ) : Patients complete response ( CR ) partial response ( PR ) completion chemotherapy receive cyclophosphamide IV 1 hour day -6 -5 , follow total body irradiation twice daily day -4 -1 . Patients minimal response completion chemotherapy receive cyclophosphamide IV 1 hour day -8 -7 , follow etoposide IV 30 hour begin day -6 , follow total body irradiation twice daily day -4 -1 . - Group B ( prior radiation great 2,000 cGy ) : Patients CR PR completion chemotherapy receive oral busulfan every 6 hour day -7 -4 , follow cyclophosphamide IV 1 hour day -3 -2 . Patients minimal response completion chemotherapy receive oral busulfan every 6 hour day -9 -6 , follow cyclophosphamide IV 1 hour day -5 -4 , follow etoposide IV 30 hour begin day -3 . - Both group : Bone marrow PBSC reinfused day 0 . Patients bulky nodal disease ( great 5 cm ) may undergo involved field radiotherapy two week transplantation . Patients follow every month 1 year . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapsed refractory cutaneous Tcell lymphoma , Hodgkin 's lymphoma , nonHodgkin 's lymphoma follow type : Diffuse small lymphocytic/marginal zone Grade I follicular small cleave cell Grade II follicular mixed cell Diffuse small cleave cell Grade III follicular large cell Diffuse mix cell Diffuse large cell Immunoblastic large cell HLA identical relate donor available Phenotypically HLA identical , MLC nonstimulatory donor eligible HLA identical relate donor available Relapse follow autologous bone marrow transplantation allow HLA identical relate donor available Eligible total body irradiation No active uncontrolled CNS disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : Over 15 physiologic age 60 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine great 2.0 mg/dL Cardiovascular : No congestive heart failure No myocardial infarction within past 3 month No significant arrhythmia require medication Resting LVEF normal Pulmonary : No significant nonneoplastic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) would preclude therapy cytotoxic drug DLCO least 50 % predicted* OR FEV1 and/or FVC least 50 % predicted* NOTE : * Unless due lymphoma , include Hodgkin 's lymphoma Other : Not pregnant Negative pregnancy test No active serious medical condition would preclude aggressive cytotoxic chemotherapy HIV negative clinical evidence AIDS PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>